1. 厚生労働省. 平成29年（2017）人口動態統計月報年計（概数）の概況.
https://www.mhlw.go.jp/toukei/saikin/hw/jinkou/geppo/nengai17/index.html [last accessed 7 January 2019]
2. 内閣府. 平成30年版高齢社会白書.
https://www8.cao.go.jp/kourei/whitepaper/w-2018/html/zenbun/index.html [last accessed 7 January 2019]
3. 内閣府男女共同参画局. 働く女性の活躍の現状と課題.
http://www.gender.go.jp/about_danjo/whitepaper/h29/zentai/html/honpen/b1_s00_01.html [last accessed 7 January 2019]
4. Cleary-Goldman J, Malone FD, Vidaver J, et al; FASTER Consortium. Impact of maternal age on obstetric outcome. Obstet Gynecol 2005;105:983-90.
5. Luke B, Brown MB. Elevated risks of pregnancy complications and adverse outcomes with increasing maternal age. Hum Reprod 2007;22:1264-72.
6. Lean SC, Derricott H, Jones RL, Heazell AEP. Advanced maternal age and adverse pregnancy outcomes: A systematic review and meta-analysis. PLoS One 2017;12:e0186287.
7. Berkowitz GS, Skovron ML, Lapinski RH, Berkowitz RL. Delayed childbearing and the outcome of pregnancy. N Engl J Med 1990;322:659-64.
8. Nishigori H, Obara T, Nishigori T, et al; Japan Environment & Children’s Study Group.
Drug Use before and during Pregnancy in Japan: The Japan Environment and Children’s Study. Pharmacy 2017;5:21.
9. Daw JR, Hanley GE, Greyson DL, Morgan SG. Prescription drug use during pregnancy in developed countries: a systematic review. Pharmacoepidemiol Drug Saf 2011;20:895-902.
− 107 −
10. Andrade SE, Raebel MA, Morse AN, et al. Use of prescription medications with a potential for fetal harm among pregnant women. Pharmacoepidemiol Drug Saf 2006;15:546-54.
11. Mitchell AA. Systematic identification of drugs that cause birth defects—a new opportunity.
N Engl J Med 2003;349:2556-9.
12. 臨床試験の一般指針. 1998年4月21日付医薬審発第380号.
13. Chobanian AV, Bakris GL, Black HR, et al; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72.
14. 日本妊娠高血圧学会. 妊娠高血圧症候群の診療指針 2015 -Best Practice Guide-.メジ カルビュー社.
15. Berg CJ, Callaghan WM, Syverson C, Henderson Z. Pregnancy-related mortality in the United States 1998-2005. Obstet Gynecol 2010;116:1302-9.
16. Roberts JM, Pearson G, Cutler J, Lindheimer M. Summary of the NHLBI Working Group on Research on Hypertension in Pregnancy. Hypertension 2003;41:437-45.
17. Bateman BT, Hernandez-Diaz S, Huybrechts KF, et al. Patterns of outpatient antihypertensive medication use during pregnancy in a Medicaid population. Hypertension 2012;60:913-20.
18. Andrade SE, Raebel MA, Brown J, et al. Outpatient use of cardiovascular drugs during pregnancy. Pharmacoepidemiol Drug Saf 2008;17:240-7.
19. 日本高血圧学会. 高血圧治療ガイドライン2014. ライフサイエンス出版.
20. Mancia G, Fagard R, Narkiewicz K, et al; Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial
− 108 −
hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013;31:1281-357.
21. Cea Soriano L, Bateman BT, García Rodríguez LA, Hernández-Díaz S. Prescription of antihypertensive medications during pregnancy in the UK. Pharmacoepidemiol Drug Saf 2014;23:1051-8.
22. Tomson T, Xue H, Battino D. Major congenital malformations in children of women with epilepsy. Seizure 2015;28:46-50.
23. Borgelt LM, Hart FM, Bainbridge JL. Epilepsy during pregnancy: focus on management strategies. Int J Womens Health 2016;8:505-17.
24. Kaneko S, Battino D, Andermann E, et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res 1999;33:145-58.
25. Harden CL, Meador KJ, Pennell PB, et al; American Academy of Neurology; American Epilepsy Society. Management issues for women with epilepsy-Focus on pregnancy (an evidence-based review): II. Teratogenesis and perinatal outcomes: Report of the Quality Standards Subcommittee and Therapeutics and Technology Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2009;50:1237-46.
26. 日本神経学会. てんかん診療ガイドライン2018. 医学書院.
27. Campbell E, Kennedy F, Russell A, et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. J Neurol Neurosurg Psychiatry 2014;85:1029-34.
28. Tomson T, Battino D, Bonizzoni E, et al; EURAP Study Group. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol 2018;17:530-8.
29. Hernández-Díaz S, Smith CR, Shen A, et al; North American AED Pregnancy Registry;
North American AED Pregnancy Registry. Comparative safety of antiepileptic drugs during
− 109 −
pregnancy. Neurology 2012;78:1692-9.30. Meador K, Reynolds MW, Crean S, Fahrbach K, Probst C. Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res 2008;81:1-13.
31. Vajda FJ, O’Brien TJ, Lander CM, Graham J, Eadie MJ. The teratogenicity of the newer antiepileptic drugs - an update. Acta Neurol Scand 2014;130:234-8.
32. Andrade SE, Gurwitz JH, Davis RL, et al. Prescription drug use in pregnancy. Am J Obstet Gynecol 2004;191:398-407.
33. Hardy JR, Holford TR, Hall GC, Bracken MB. Strategies for identifying pregnancies in the automated medical records of the General Practice Research Database. Pharmacoepidemiol Drug Saf 2004;13:749-59.
34. Manson JM, McFarland B, Weiss S. Use of an automated database to evaluate markers for early detection of pregnancy. Am J Epidemiol 2001;154:180-7.
35. Charlton R, Garne E, Wang H, et al. Antiepileptic drug prescribing before, during and after pregnancy: a study in seven European regions. Pharmacoepidemiol Drug Saf 2015;24:1144-54.
36. Bérard A, Sheehy O, Zhao JP, Nordeng H. Use of macrolides during pregnancy and the risk of birth defects: a population-based study. Pharmacoepidemiol Drug Saf 2015;24:1241-8.
37. Snowball J, de Vries C. Determination of pregnancy on the General Practice Research Database. Pharmacoepidemiol Drug Saf 2007;16:S118.
38. Vilain A, Otis S, Forget A, Blais L. Agreement between administrative databases and medical charts for pregnancy-related variables among asthmatic women.
Pharmacoepidemiol Drug Saf 2008;17:345-53.
− 110 −
39. Toh S, Mitchell AA, Werler MM, Hernández-Díaz S. Sensitivity and specificity of computerized algorithms to classify gestational periods in the absence of information on date of conception. Am J Epidemiol 2008;167:633-40.
40. Margulis AV, Setoguchi S, Mittleman MA, Glynn RJ, Dormuth CR, Hernández-Díaz S.
Algorithms to estimate the beginning of pregnancy in administrative databases.
Pharmacoepidemiol Drug Saf 2013;22:16-24.
41. Raebel MA, Ellis JL, Andrade SE. Evaluation of gestational age and admission date assumptions used to determine prenatal drug exposure from administrative data.
Pharmacoepidemiol Drug Saf. 2005;14:829-36.
42. Li Q, Andrade SE, Cooper WO, et al. Validation of an algorithm to estimate gestational age in electronic health plan databases. Pharmacoepidemiol Drug Saf 2013;22:524-32.
43. Margulis AV, Palmsten K, Andrade SE, et al. Beginning and duration of pregnancy in automated health care databases: review of estimation methods and validation results.
Pharmacoepidemiol Drug Saf 2015;24:335-42.
44. Strom BL, Carson JL. Use of automated databases for pharmacoepidemiology research.
Epidemiol Rev 1990;12:87-107.
45. Kimura S, Sato T, Ikeda S, Noda M, Nakayama T. Development of a database of health insurance claims: standardization of disease classifications and anonymous record linkage.
J Epidemiol 2010;20:413-9.
46. Matsuzaki Y, Takahashi F, Yamaguchi M, Uyama Y, On Behalf of MID-NET Project Group.
Progress and Future of Medical Information Database Network (MID-NET®) Project.
Pharmacoepidemiol and Drug Saf 2016;25(Suppl. 3):607.
47. Ooba N, Setoguchi S, Ando T, et al. Claims-based definition of death in Japanese claims database: validity and implications. PLoS One 2013;8:e66116.
− 111 −
48. 日本薬剤疫学会. 日本で薬剤疫学研究に利用可能なデータベース.
http://www.jspe.jp/mt-static/FileUpload/files/JSPE_DB_TF_J.PDF [last accessed 7 January 2019].
49. MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 1991;338:131-7.
50. De Wals P, Tairou F, Van Allen MI, et al. Reduction in neural-tube defects after folic acid fortification in Canada. N Engl J Med 2007;357:135-42.
51. 厚生省児童家庭局母子保健課長，保健医療局地域保健・健康増進栄養課生活習慣病 対策室長通知. 神経管閉鎖障害の発症リスク低減のための妊娠可能な年齢の女性等 に対する葉酸の摂取に係る適切な情報提供の推進について. 平成12年12月28日. 52. US Preventive Services Task Force. Folic Acid Supplementation for the Prevention of
Neural Tube Defects: US Preventive Services Task Force Recommendation Statement.
JAMA 2017;317:183-9.
53. Food Fortification Initiative. Global Progress. Available from:
http://www.ffinetwork.org/global_progress/ [last accessed 7 January 2019]
54. Mills JL, Signore C. Neural tube defect rates before and after food fortification with folic acid. Birth Defects Res A Clin Mol Teratol 2004;70:844-5.
55. International Clearinghouse for Birth Defects Surveillance and Research. Annual Report 2014. Available from: http://www.icbdsr.org/wp-content/annual_report/Report2014.pdf [last accessed 7 January 2019]
56. Smith MA, Lau C. A resolution on folic acid fortification. Birth Defects Res A Clin Mol Teratol 2015;103:1-2.
57. Kondo A, Morota N, Date H, et al. Awareness of folic acid use increases its consumption, and reduces the risk of spina bifida. Br J Nutr 2015;114:84-90.
58. Kawamoto T, Nitta H, Murata K, et al. Rationale and study design of the Japan
− 112 −
environment and children's study (JECS). BMC Public Health 2014;14:25.
59. Michikawa T, Nitta H, Nakayama SF, et al. Baseline profile of participants in the Japan Environment and Children’s Study (JECS). J Epidemiol 2018;28:99-104.
60. Yasunaga H, Ide H, Imamura T, Ohe K. Impact of the Japanese Diagnosis Procedure Combination-based Payment System on cardiovascular medicine-related costs. Int Heart J 2005;46:855-66.
61. Matsuda S, Fujimori K, Kuwabara K, Kohichi B, Ishikawa KF. Diagnosis Procedure Combination as an infrastructure for the clinical study. Asian Pacific J Dis Manag 2011;5:81-7.
62. Yamana H, Moriwaki M, Horiguchi H, et al. Validity of diagnoses, procedures, and laboratory data in Japanese administrative data. J Epidemiol 2017;27:476-82.
63. 日本産科婦人科学会, 日本産婦人科医会. 産婦人科診療ガイドライン―産科編2014.
日本産科婦人科学会.
64. Waage CW, Mdala I, Jenum AK, Michelsen TM, Birkeland KI, Sletner L. Ethnic differences in blood pressure from early pregnancy to postpartum: a Norwegian cohort study. J Hypertens 2016;34:1151-9.
65. Ghosh G, Grewal J, Männistö T, et al. Racial/ethnic differences in pregnancy-related hypertensive disease in nulliparous women. Ethn Dis 2014;24:283-9.
66. Chappell LC, Seed P, Enye S, Briley AL, Poston L, Shennan AH. Clinical and geographical variation in prophylactic and therapeutic treatments for pre-eclampsia in the UK. BJOG 2010;117:695-700.
67. 日高敦夫, 中本収, 江口勝人, 古橋信晃, 山口賢二. 重症妊娠中毒症の薬物療法【重 症妊娠中毒症ケースカード調査No. 6】. 日本妊娠中毒症学会雑誌 1998;6:203-14.
68. Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al; Heart Failure Association of the European Society of Cardiology Working Group on Peripartum Cardiomyopathy. Current state of
− 113 −
knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail 2010;12:767-78.
69. Sliwa K, Fett J, Elkayam U. Peripartum cardiomyopathy. Lancet 2006;368:687-93.
70. Hilfiker-Kleiner D, Haghikia A, Nonhoff J, Bauersachs J. Peripartum cardiomyopathy:
current management and future perspectives. Eur Heart J 2015;36:1090-7.
71. Bullo M, Tschumi S, Bucher BS, Bianchetti MG, Simonetti GD. Pregnancy outcome following exposure to angiotensin converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review. Hypertension 2012;60:444-50.
72. Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006;354:2443-51.
73. Barr M Jr. Teratogen update: angiotensin-converting enzyme inhibitors. Teratology 1994;
50:399-409.
74. Gersak K, Cvijic M, Cerar LK. Angiotensin II receptor blockers in pregnancy: a report of five cases. Reprod Toxicol 2009;28:109-12.
75. Serreau R, Luton D, Macher MA, Delezoide AL, Garel C, Jacqz-Aigrain E. Developmental toxicity of the angiotensin II type 1 receptor antagonists during human pregnancy: a report of 10 cases. BJOG 2005;112:710-2.
76. Karthikeyan VJ, Ferner RE, Baghdadi S, Lane DA, Lip GY, Beevers DG. Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers safe in pregnancy: a report of ninety-one pregnancies. J Hypertens 2011;29:396-9.
77. Manzur-Verástegui S, Mandeville PB, Gordillo-Moscoso A, Hernández-Sierra JF, Rodríguez-Martínez M. Efficacy of nitroglycerine infusion versus sublingual nifedipine in severe pre-eclampsia: a randomized, triple-blind, controlled trial. Clin Exp Pharmacol
− 114 −
Physiol 2008;35:580-5.78. てんかん診療ネットワークウェブサイト.
https://www.ecn-japan.com/general/investigate/ [last accessed 7 January 2019].
79. Bobo WV, Davis RL, Toh S, et al. Trends in the Use of antiepileptic drugs among pregnant women in the US, 2001–2007: a medication exposure in pregnancy risk evaluation program study. Paediatr Perinat Epidemiol 2012;26:578-88.
80. Christensen J, Grønborg TK, Sørensen MJ, et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA 2013;309:1696-703.
81. Meador KJ , Baker GA, Browning N, et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol 2013;12:244-52.
82. Mulleners WM, Chronicle EP. Anticonvulsants in migraine prophylaxis: a Cochrane review.
Cephalalgia 2008;28:585-97.
83. Smith LA, Cornelius V, Warnock A, Tacchi MJ, Taylor D. Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials.
Bipolar Disord 2007;9:551-60.
84. Yildiz A, Vieta E, Leucht S, Baldessarini RJ. Efficacy of antimanic treatments:
meta-analysis of randomized, controlled trials. Neuropsychopharmacology 2011;36:375-89.
85. Zesiewicz TA, Elble R, Louis ED, et al; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: therapies for essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2005;64:2008-20.
86. Werler MM, Louik C, Mitchell AA. Achieving a public health recommendation for preventing neural tube defects with folic acid. Am J Public Health. 1999;89:1637-40.
− 115 −
87. Shaw GM, Schaffer D, Velie EM, et al. Periconceptional vitamin use, dietary folate, and the occurrence of neural tube defects. Epidemiology 1995;6:219-26.
88. Obara T, Nishigori H, Nishigori T, et al. Prevalence and determinants of inadequate use of folic acid supplementation in Japanese pregnant women: the Japan Environment and Children's Study (JECS). J Matern Fetal Neonatal Med 2017;30:588-93.
89. Nilsen RM, Leoncini E, Gastaldi P, et al. Prevalence and determinants of preconception folic acid use: an Italian multicenter survey. Ital J Pediatr 2016;42:65.
90. Xing XY, Tao FB, Hao JH, et al. Periconceptional folic acid supplementation among women attending antenatal clinic in Anhui, China: data from a population-based cohort study. Midwifery 2012;28:291-7.
91. Timmermans S, Jaddoe VW, Mackenbach JP, Hofman A, Steegers-Theunissen RP, Steegers EA. Determinants of folic acid use in early pregnancy in a multi-ethnic urban population in The Netherlands: the Generation R study. Prev Med 2008;47:427-32.
92. Nilsen RM, Vollset SE, Gjessing HK, et al. Patterns and predictors of folic acid supplement use among pregnant women: the Norwegian Mother and Child Cohort Study. Am J Clin Nutr 2006;84:1134-41.
93. Forster DA, Wills G, Denning A, et al. The use of folic acid and other vitamins before and during pregnancy in a group of women in Melbourne, Australia. Midwifery 2009;25:134-46.
94. de Jong-Van den Berg LT, Hernandez-Diaz S, Werler MM, et al. Trends and predictors of folic acid awareness and periconceptional use in pregnant women. Am J Obstet Gynecol 2005;192:121-8.
95. Tort J, Lelong N, Prunet C, et al. Maternal and health care determinants of preconceptional use of folic acid supplementation in France: results from the 2010 National Perinatal Survey. BJOG 2013;120:1661-7.
− 116 −
96. Toivonen KI, Oinonen KA, Duchene KM. Preconception health behaviours: A scoping review. Prev Med 2017;96:1-15.
97. Morin P, De Wals P, St-Cyr-Tribble D, et al. Pregnancy planning: a determinant of folic acid supplements use for the primary prevention of neural tube defects. Can J Public Health 2002;93:259-63.
98. Feldkamp M, Friedrichs M, Marti K. Folic acid awareness, knowledge, and consumption among women of childbearing age in Utah, 1998-2000. Am J Med Genet 2002;107:67-9.
99. Kondo A, Yamamoto S, Inoue H, et al. Folic acid in the prevention of neural tube defects:
awareness among laywomen and healthcare providers in Japan. Congenit Anom (Kyoto) 2009;49:97-101.
100. Matsuo T, Kagohashi Y, Senga Y, et al. Survey on awareness of folic acid recognition and intake by female students. Congenit Anom (Kyoto) 2017;57:166-70.
101. Yerby MS. Management issues for women with epilepsy: neural tube defects and folic acid supplementation. Neurology 2003;61(6 Suppl 2):S23-6.
102. Makol A, Wright K, Amin S. Rheumatoid arthritis and pregnancy: safety considerations in pharmacological management. Drugs 2011;71:1973-87.
103. McDonnell R, Johnson Z, Doyle A, et al. Determinants of folic acid knowledge and use among antenatal women. J Public Health Med 1999;21:145-9.
104. Sen S, Manzoor A, Deviasumathy M, et al. Maternal knowledge, attitude and practice regarding folic acid intake during the periconceptional period. Public Health Nutr 2001;4:909-12.
105. Cleves MA, Hobbs CA, Collins HB, et al. Folic acid use by women receiving routine gynecologic care. Obstet Gynecol 2004;103:746-53.
106. Knudsen VK, Orozova-Bekkevold I, Rasmussen LB, et al. Low compliance with recommendations on folic acid use in relation to pregnancy: is there a need for
− 117 −
fortification? Public Health Nutr 2004;7:843-50.107. Carmichael SL, Shaw GM, Yang W, et al. Correlates of intake of folic acid-containing supplements among pregnant women. Am J Obstet Gynecol 2006;194:203-10.
108. Zeng Z, Yuan P, Wang Y, et al. Folic acid awareness and intake among women in areas with high prevalence of neural tube defects in China: a cross-sectional study. Public Health Nutr 2011;14:1142-7.
109. Viswanathan M, Treiman KA, Kish-Doto J, et al. Folic Acid Supplementation for the Prevention of Neural Tube Defects: An Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2017;317:190-203.
110. 日本先天異常学会. 改訂版：日本先天異常学会からのメッセージ－葉酸サプリメン
トの摂取により神経管閉鎖障害の発症リスクを減らしまょう. 2018 年 3 月 27 日. http://jts.umin.jp/new/JTS_message2018_j.pdf [last accessed 7 January 2019].